Details for Patent: 10,683,499
Which drugs does patent 10,683,499 protect, and when does it expire?
Patent 10,683,499 protects WAINUA and WAINUA (AUTOINJECTOR) and is included in one NDA.
This patent has two hundred and seventy-seven patent family members in forty countries.
Summary for Patent: 10,683,499
| Title: | Compositions and methods for modulating TTR expression |
| Abstract: | Provided herein are oligomeric compounds with conjugate groups. In certain embodiments, the oligomeric compounds are conjugated to N-Acetylgalactosamine. |
| Inventor(s): | Thazha P. Prakash, Punit P. Seth, Eric E. Swayze |
| Assignee: | Glaxo Group Ltd , Ionis Pharmaceuticals Inc |
| Application Number: | US15/687,306 |
|
Patent Claim Types: see list of patent claims | Use; Composition; |
Drugs Protected by US Patent 10,683,499
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Astrazeneca Ab | WAINUA | eplontersen sodium | SOLUTION;SUBCUTANEOUS | 217388-002 | Apr 15, 2026 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | Y | Y | TREATMENT OF POLYNEUROPATHY OF HEREDITARY TRANSTHYRETIN-MEDIATED AMYLOIDOSIS | ⤷ Start Trial | ||
| Astrazeneca Ab | WAINUA (AUTOINJECTOR) | eplontersen sodium | SOLUTION;SUBCUTANEOUS | 217388-001 | Dec 21, 2023 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | Y | Y | TREATMENT OF POLYNEUROPATHY OF HEREDITARY TRANSTHYRETIN-MEDIATED AMYLOIDOSIS | ⤷ Start Trial | ||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 10,683,499
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| European Patent Office | 3524680 | ⤷ Start Trial | CA 2025 00027 | Denmark | ⤷ Start Trial |
| European Patent Office | 3524680 | ⤷ Start Trial | C20250028 | Finland | ⤷ Start Trial |
| European Patent Office | 3524680 | ⤷ Start Trial | 301341 | Netherlands | ⤷ Start Trial |
| European Patent Office | 3524680 | ⤷ Start Trial | 122025000044 | Germany | ⤷ Start Trial |
| European Patent Office | 3524680 | ⤷ Start Trial | 2025C/700 | Belgium | ⤷ Start Trial |
| European Patent Office | 2991656 | ⤷ Start Trial | C20260001 | Finland | ⤷ Start Trial |
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
